Protara Therapeutics (NASDAQ:TARA) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Protara Therapeutics (NASDAQ:TARA) posted its quarterly earnings data on Friday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.02, FiscalAI reports.

Protara Therapeutics Price Performance

Shares of NASDAQ TARA traded up $0.17 during midday trading on Friday, reaching $2.30. 690,546 shares of the stock were exchanged, compared to its average volume of 888,528. Protara Therapeutics has a 12 month low of $2.09 and a 12 month high of $7.82. The company has a market capitalization of $135.92 million, a price-to-earnings ratio of -1.70 and a beta of 1.54. The business has a 50-day simple moving average of $3.06 and a two-hundred day simple moving average of $4.51.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TARA. Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.25.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.

Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.